Genprex Inc Stock Price, News & Analysis

Genprex, Inc. (NASDAQ: GNPX) announced the dosing of the first patient in its Acclaim-1 clinical trial, evaluating its lead drug, REQORSA, in combination with Tagrisso for late-stage non-small cell lung cancer (NSCLC) patients. This Phase 1/2 trial aims to improve responses in patients whose disease progressed after Tagrisso treatment. The FDA previously granted Fast Track Designation to REQORSA for this patient population. Positive preclinical data indicate that REQORSA may overcome resistance to Tagrisso.

Genprex, Inc. (NASDAQ: GNPX) announced that President and CEO Rodney Varner will discuss the Company's innovative gene therapies for cancer and diabetes at the upcoming BIO CEO and Investor Conference and Diamond Equity Research Conference. The BIO conference is scheduled for February 14-17, 2022, with on-demand presentations available starting February 11. The Diamond conference will take place on February 24, 2022, at 3 p.m. EST. These events will allow for virtual one-on-one meetings and follow-up questions. For more information, visit www.genprex.com.

Genprex, Inc. (NASDAQ: GNPX) announced promising preclinical findings in a study published in Cancers, demonstrating that its ONCOPREX® Nanoparticle Delivery System effectively restores FAS expression in mouse models of metastatic colorectal cancer. This delivery system showed potential in suppressing tumor growth and increasing survival rates. The company plans to expand its oncology programs, leveraging these results to explore additional therapeutic genes for various cancers. The ONCOPREX system is also pivotal in Genprex's ongoing lung cancer trials.

Genprex, Inc. has announced plans to accelerate the opening of clinical trial sites for the Acclaim-1 trial, which investigates the combination of REQORSA™ and AstraZeneca's Tagrisso® in treating non-small cell lung cancer (NSCLC). Four sites are opening to enroll patients in the Phase 1 portion of the trial, with additional sites anticipated for Phase 2. The trial will evaluate the therapy’s efficacy in patients previously treated with Tagrisso. An interim analysis will be conducted at 25 events, and the Phase 2 primary endpoint is progression-free survival.

Genprex, a clinical-stage gene therapy company (NASDAQ: GNPX), announced its participation in key investor and healthcare conferences in January 2022. CEO Rodney Varner and CMO Mark Berger will lead presentations at events including the HC Wainwright BIOCONNECT, Biotech Showcase, and the Precision Lung Cancer World R&D Summit. The CEO Roadshow presentation is scheduled for January 26, 2022. Genprex focuses on developing gene therapies for cancer and diabetes, utilizing their proprietary ONCOPREX® delivery system. REQORSA™, their lead candidate for lung cancer, has received Fast Track Designation from the FDA.

Genprex, Inc. (NASDAQ: GNPX) has expanded its research pipeline to include small cell lung cancer (SCLC) for its lead drug candidate, REQORSA™. SCLC accounts for 10-15% of the lung cancer market, while non-small cell lung cancer (NSCLC) represents 84%. The Chief Medical Officer noted that REQORSA might be effective due to low TUSC2 protein levels in SCLC. The company aims to address unmet medical needs in cancer treatments, potentially improving patient outcomes significantly.

Genprex, Inc. (NASDAQ: GNPX) announced that the FDA granted a second Fast Track Designation for its lead drug candidate, REQORSA Immunogene Therapy. This designation applies to the drug used in combination with Keytruda for patients with late-stage non-small cell lung cancer (NSCLC). Genprex plans to start the Acclaim-2 clinical trial in early 2022. As of Q3 2021, the Company had a strong cash position of $42 million, positioning it well for clinical development efforts in 2022.

Genprex, Inc. (NASDAQ: GNPX) announced its President and CEO, Rodney Varner, will present at the CEO Roadshow on November 17 at 11 a.m. ET. The webinar will focus on Genprex's innovative gene therapies targeting cancer and diabetes. Attendees will have an opportunity for questions post-presentation. The session will be recorded and accessible on Genprex’s website. Genprex specializes in advanced gene therapy solutions, including its lead product REQORSA™, aimed at treating non-small cell lung cancer.

Genprex, Inc. strengthens its leadership team by appointing Mark S. Berger, M.D. as Chief Medical Officer and Hemant Kumar, Ph.D. as Chief Manufacturing and Technology Officer. These additions come as the company advances its Acclaim-1 and Acclaim-2 clinical trials for REQORSA, a systemic gene therapy targeting non-small cell lung cancer (NSCLC). Both leaders bring extensive experience in oncology and gene therapy, aiming to enhance Genprex's pipeline and clinical strategy. Additionally, they were granted stock options at an exercise price of $2.85.